FY2024 EPS Forecast for Sensus Healthcare Lifted by Analyst

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Equities research analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Sensus Healthcare in a research report issued to clients and investors on Monday, November 18th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of $0.42 for the year, up from their previous forecast of $0.36. HC Wainwright currently has a "Buy" rating and a $11.00 target price on the stock. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.38 per share. HC Wainwright also issued estimates for Sensus Healthcare's Q4 2024 earnings at $0.11 EPS, Q1 2025 earnings at $0.14 EPS, Q2 2025 earnings at $0.10 EPS and FY2025 earnings at $0.52 EPS.

Separately, Maxim Group upped their price target on Sensus Healthcare from $12.00 to $14.00 and gave the company a "buy" rating in a research report on Friday.

Sensus Healthcare Stock Performance

Shares of SRTS stock traded down $0.04 during trading hours on Tuesday, hitting $8.37. 364,185 shares of the company were exchanged, compared to its average volume of 278,938. The stock has a market capitalization of $137.10 million, a price-to-earnings ratio of 14.75 and a beta of 1.04. Sensus Healthcare has a one year low of $2.02 and a one year high of $8.69. The business's 50-day simple moving average is $6.42 and its two-hundred day simple moving average is $6.00.

Institutional Trading of Sensus Healthcare

Hedge funds have recently added to or reduced their stakes in the business. Truvestments Capital LLC bought a new position in shares of Sensus Healthcare in the third quarter valued at approximately $32,000. Chapin Davis Inc. bought a new position in Sensus Healthcare during the 2nd quarter valued at $53,000. Geode Capital Management LLC increased its position in shares of Sensus Healthcare by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company's stock valued at $849,000 after purchasing an additional 11,525 shares during the period. Sachetta LLC raised its stake in shares of Sensus Healthcare by 12.9% in the 2nd quarter. Sachetta LLC now owns 118,354 shares of the company's stock worth $631,000 after buying an additional 13,544 shares in the last quarter. Finally, XTX Topco Ltd lifted its holdings in shares of Sensus Healthcare by 76.0% in the third quarter. XTX Topco Ltd now owns 31,530 shares of the company's stock valued at $183,000 after buying an additional 13,619 shares during the period. Institutional investors own 25.30% of the company's stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.